Fedex Securities Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Letter of Offer for the attention of the Public Shareholders of Parmax Pharma Ltd ("Target Company").

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001, Maharashtra, India. Sub: Submission Copy of Letter of Offer to the Public Shareholders of Parmax Pharma Limited Scrip ID: PARMAX | Scrip Code: 540359 Ref: Open offer for acquisition of upto 23,46,250 (Twenty-Three Lakhs Forty-Six Thousand Two Hundred and Fifty) fully paid-up equity shares of face value of ₹ 10.00 each (“Equity Shares”) of Parmax Pharma Limited (the “Target Company”), representing 26.00% (Twenty-Six Percent) of the Expanded Voting Share Capital of the Target Company from the Public Shareholders of the Target Company by Dhiren Chandulal Shah (“Acquirer 1”) and Sunil Chinubhai Shah (“Acquirer 2”) hereinafter collectively referred to as the (“Acquirers”) along with Dhairya Dhiren Shah (“PAC 1”), Hiren Pravin Doshi (“PAC 2”), Sheetal Hiren Doshi (“PAC 3”), Nirmal Sunilbhai Shah (“PAC 4”), Rupa Sunil Shah (“PAC 5”), Vijaykumar Natvarlal Shiyani (“PAC 6”), Kamlesh Natvarlal Shiyani (“PAC 7”), Abhay Chinubhai Shah (“PAC 8”), Umang Alkesh Gosalia (“PAC 9”) and Meena Alkesh Gosalia (“PAC 10”) ( (PAC 1, PAC 2, PAC 3, PAC 4, PAC 4, PAC 5, PAC 6, PAC 7, PAC 8, PAC 9 and PAC 10, collectively referred to as the “PACs”), in their capacity as persons acting in concert with the Acquirers for the purposes of the Open Offer (“Offer” or “Open Offer”). Dear Sir/Madam, In relation to the captioned offer, we, Fedex Securities Private Limited, Manager to the Open Offer, herewith enclosed the Copy of Letter of Offer (LOF), in accordance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended. Further, the LOF has been made in conformity with all the provisions of the SEBI SAST regulations and the format of the LOF specified by the SEBI. Kindly acknowledge and take the same on your record. Thanking You, Yours faithfully, For Fedex Securities Private Limited Antara Chogle Manager Date: July 21, 2026 Place: Mumbai LETTER OF OFFER THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION This Letter of offer (“LOF”) is being sent to you as a Public Shareholder (as defined below) of Parmax Pharma Limited (“Target Company”). If you require any clarifications about the action to be taken, you may consult your stockbroker or investment consultant or the Manager to the Offer (as defined below)/Registrar to the Offer (as defined below). In case you have recently sold your Equity Shares (as defined below) in the Target Company, please hand over this LOF and the accompanying Form of Acceptance-cum- Acknowledgement (as defined below) and transfer deed to the member of Stock Exchange (as defined below) through whom the said sale was affected. OPEN OFFER (“OPEN OFFER”/ “OFFER”) DHIREN CHANDULAL SHAH (“Acquirer 1”) Residential Address: 1101, 11th Floor, The Art House, V. M. Road, J.V.P.D. Scheme, 20 Swastik Society, Vile Parle (West), Mumbai, Maharashtra, 400056, India Tel: +91 9820232662 Email: dhiren@ecmpl.com SUNIL CHINUBHAI SHAH (“Acquirer 2”) Residential Address: 31, Vidyabhavan, 22/39 New Jagnath Plot, Dr. Yagnik Road, Rajkot, Gujarat, 360001 Tel: +91 9824238781 Email: rishachemindia@gmail.com (Acquirer 1 and Acquirer 2 are hereinafter collectively referred to as “Acquirers”) ALONG WITH DHAIRYA DHIREN SHAH (“PAC 1”) Residential Address: Plot No. 20, 12th Floor, The Art House, VL Mehta Road, Swastik Society, J.V.P.D. Scheme, Vile Parle (West), Mumbai, Maharashtra, 400056, India Tel: +91 9004426662 Email: dhairya@ecmpl.com HIREN PRAVIN DOSHI (“PAC 2”) Residential Address: 206/C, Dharam Palace, 2nd Floor, Hughes Road, Near Sukh Sagar, Gamdevi, Grant Road, Mumbai, Maharashtra, 400007, India. Tel: +91 9323211054 Email: hiren@signpharma.com SHEETAL HIREN DOSHI (“PAC 3”) Residential Address: 206/C, Dharam Palace,2nd Floor, Hughes Road, Near Sukh Sagar, Gamdevi, Grant Road, Mumbai, Maharashtra, 400007, India. Tel: +91 9833111054 Email: sheetal.doshi23@gmail.com NIRMAL SUNILBHAI SHAH (“PAC 4”) Residential Address: Vidyabhavan, 22/39 New Jaganath Plot, Dr. Yagnik Road, Rajkot, Gujarat. Tel: +91 7228896827 Email: shah01nirmal@gmail.com RUPA SUNIL SHAH (“PAC 5”) Residential Address: Vidyabhavan, 22/39 New Jaganath Plot, Dr. Yagnik Road, Rajkot, Gujarat. Tel: +91 9904254092 Email: shahnirmal7868150@gmail.com VIJAYKUMAR NATVARLAL SHIYANI (“PAC 6”) Residential Address: Shivam, 3-Sardar Nagar Co. Op. Society, Mavdi Road, Rajkot, Gujarat, 360004, India. Tel: +91 9824212092 Email: vijay.n.shiyani@gmail.com KAMLESH NATVARLAL SHIYANI (“PAC 7”) Residential Address: Shivam-3, Sardar Nagar Co. Op. Society, Mavdi Road, Rajkot, Gujarat, 360004, India. Tel: +91 9824499334 Email: kamlesh.shiyani74@gmail.com ABHAY CHINUBHAI SHAH (“PAC 8”) Residential Address: 523 Cambridge Ave, Westbury, New York – 11590. Tel: + 5169967845 Email: shahabhay01@gmail.com UMANG ALKESH GOSALIA (PAC 9) Residential Address: A-1102, Bilipatra Apartment, B/H Balaji Hall, off. 150 Ft. Ring Road, Nr. K.G Dholakiya School, Rajkot, Gujarat, 360004, India. Tel: +91 9924544911 Email: umang.gosalia@yahoo.in MEENA ALKESH GOSALIA (PAC 10) Residential Address: A-1102, Bilipatra Apartment, B/H Balaji Hall, off. 150 ft. Ring Road, Near K.G Dholakiya School, Rajkot, Gujarat – 360004. Tel: +91 9924044911 Email: umang.gosalia@yahoo.in (PAC 1, PAC 2, PAC 3, PAC 4, PAC 5, PAC 6, PAC 7, PAC 8, PAC 9 and PAC 10 are hereinafter collectively referred to as PAC(s)) TO ACQUIRE UP TO 23,46,250 (TWENTY-THREE LAKHS FORTY-SIX THOUSAND TWO HUNDRED AND FIFTY) FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10/- (INDIAN RUPEES TEN) EACH (“OFFER SHARES”), REPRESENTING 26.00% (TWENTY-SIX PERCENT) OF THE EXPANDED VOTING CAPITAL (AS DEFINED BELOW) OF THE TARGET COMPANY, FOR CASH AT A PRICE OF ₹ 42.80/- (INDIAN RUPEES FORTY-TWO AND EIGHT ZERO PAISE ONLY) PER EQUITY SHARE (“OFFER PRICE”) , IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011, AS AMENDED (“SEBI (SAST) REGULATIONS”), FROM THE PUBLIC SHAREHOLDERS OF PARMAX PHARMA LIMITED (“Target Company”) A public limited company incorporated under the Indian Companies Act, 1956 Registered Office at: Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Rajkot, Gujarat, 360311; Tel: +91 02827-270534; Email: cs@parmaxpharma.com; Website: www.parmaxpharma.com; Corporate Identification Number: L24231GJ1994PLC023504; Please Note: 1. This Open Offer is being made by the Acquirers and the PACs to the Public Shareholders of the Target Company, in accordance with Regulations 3(1) and 4 and other applicable regulations of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto (“SEBI (SAST) Regulations”). 2. The Offer Price is ₹ 42.80/- (Indian Rupees Forty-Two and Eight Zero Paise Only) per Equity Share, payable in cash. 3. This Open Offer is not conditional upon any minimum level of acceptance in terms of Regulation 19 of SEBI (SAST) Regulations. 4. This Open Offer is not a competing offer in terms of Regulation 20 of the SEBI (SAST) Regulations. 5. As per the Information available with the Acquirers, the PACs and the Target Company, there is no competing offer as on the date of this Letter of Offer. The last date for making such competing offer has expired. 6. As on date of this letter of offer (“Letter of Offer” or “LOF”), no statutory or other approval(s) required to acquire the Equity Shares that are validly tendered pursuant to this Offer, save and except as detailed in paragraph 8.4 of this LOF. However, if any statutory or other approval(s) becomes applicable or are required by the Acquirers and/or the PACs at a later date prior to the completion of the Offer, the Offer would also be subject to such statutory or other approval(s) being obtained. Where any statutory or other approval extends to some but not all of the Public Shareholders, the Acquirers shall have the option to make pay [Showing first 8,000 characters — download PDF for full document]